Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  EXACT Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/12/2019 09/13/2019 09/16/2019 09/17/2019 09/18/2019 Date
108.69(c) 106.71(c) 104.41(c) 106.87(c) 105.44(c) Last
1 893 098 1 135 648 1 266 891 1 314 530 1 908 429 Volume
+0.08% -1.82% -2.16% +2.36% -1.34% Change
More quotes
Financials (USD)
Sales 2019 811 M
EBIT 2019 -193 M
Net income 2019 -218 M
Finance 2019 270 M
Yield 2019 -
Sales 2020 1 179 M
EBIT 2020 -90,6 M
Net income 2020 -105 M
Finance 2020 173 M
Yield 2020 -
P/E ratio 2019 -61,8x
P/E ratio 2020 -133x
EV / Sales2019 16,5x
EV / Sales2020 11,4x
Capitalization 13 653 M
More Financials
Company
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based... 
More about the company
Surperformance© ratings of EXACT Sciences Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on EXACT SCIENCES CORPORATION
07/30EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
07/30EXACT SCIENCES CORP : Entry into a Material Definitive Agreement, Financial Stat..
AQ
07/30EXACT SCIENCES : buys Genomic in $2.8bn deal
AQ
07/29Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal
RE
07/29EXACT SCIENCES : Cancer diagnostic firms to join in $2.8 billion deal
AQ
07/29GLOBAL MARKETS LIVE : Sprint, T-Mobile, Refinitiv, Pfizer…
07/29EXACT SCIENCES CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/29EXACT SCIENCES : 2Q Earnings Snapshot
AQ
07/27EXACT SCIENCES IN ADVANCED TALKS TO : Bloomberg
RE
07/26EXACT SCIENCES CORP : Entry into a Material Definitive Agreement, Change in Dire..
AQ
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Sector news : Biotechnology & Medical Research - NEC
09/18BIOGEN : to Study Higher Dose of Spinraza in Spinal Muscular Atrophy
DJ
09/16A Plan to Fight Hep C -- WSJ
DJ
09/03Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals
RE
08/29GLOBAL MARKETS LIVE : Dell, United Airlines, UBS, Apple…
08/28U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight
RE
More sector news : Biotechnology & Medical Research - NEC
Chart EXACT SCIENCES CORPORATION
Duration : Period :
EXACT Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 133,44  $
Last Close Price 105,44  $
Spread / Highest target 35,6%
Spread / Average Target 26,6%
Spread / Lowest Target 20,4%
EPS Revisions
Managers
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey T. Elliott Chief Financial Officer
Barry M. Berger Co-Chief Medical Officer & Head-Medical Affairs
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Gary Frings Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION67.10%13 838
IQVIA HOLDINGS INC32.08%29 960
LONZA GROUP32.98%25 321
CELLTRION, INC.--.--%18 395
INCYTE CORPORATION24.39%17 012
SEATTLE GENETICS, INC.28.54%12 150